Among the diffuse aggressive lymphomas, diffuse large-cell histology (DLCL) is most common. In the past, older patients often received dose-reduced, potentially curative, aggressive regimens.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Kymriah was cleared by the FDA for the follicular lymphoma use last year as well, a little after Yescarta, adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

Of these patients, 30% had de novo diffuse large B-cell lymphoma, 17% had low-grade follicular lymphoma, 8% had transformed indolent non-Hodgkin lymphoma or grade 3B follicular lymphoma ...

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

The incidence of non-Hodgkin’s lymphoma (NHL ... characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients are reviewed, as well ...